

# Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/OEC1A76C4BEBEN.html>

Date: March 2022

Pages: 66

Price: US\$ 2,000.00 (Single User License)

ID: OEC1A76C4BEBEN

## Abstracts

Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 8, 2, 5, 1 and 3 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Onychomycosis (Tinea Unguim) - Overview

Onychomycosis (Tinea Unguim) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Onychomycosis (Tinea Unguim) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Onychomycosis (Tinea Unguim) - Companies Involved in Therapeutics Development

Acea Biotech Inc

Almirall SA

Amtixbio Co Ltd

ASCIL Biopharm

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Infextious Therapeutic

Kaken Pharmaceutical Co Ltd

Moberg Pharma AB

Mycovia Pharmaceuticals Inc

NAL Pharmaceuticals Ltd

Nektr Technologies Ltd

Novabiotics Ltd

Photonamic GmbH & Co KG

SaNOtize Research and Development Corp

TTY Biopharm Co Ltd

Turn Therapeutics Inc

Onychomycosis (Tinea Unguim) - Drug Profiles

A-31S - Drug Profile

Product Description

Mechanism Of Action

History of Events

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

ATB-1651 - Drug Profile

Product Description

Mechanism Of Action

BB-0305 - Drug Profile

Product Description

Mechanism Of Action

History of Events

benzalkonium chloride + polyhexanide - Drug Profile

Product Description

Mechanism Of Action

DBI-001 - Drug Profile

Product Description

Mechanism Of Action

efinaconazole - Drug Profile

Product Description

Mechanism Of Action

History of Events

ELS-160 - Drug Profile

Product Description

Mechanism Of Action

IFX-103 - Drug Profile

Product Description

Mechanism Of Action

KP-607 - Drug Profile

Product Description

Mechanism Of Action

NAL-3210 - Drug Profile

Product Description

Mechanism Of Action

NORS-0791 - Drug Profile

Product Description  
Mechanism Of Action  
NP-213 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
onymed - Drug Profile  
Product Description  
Mechanism Of Action  
oteseconazole - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
P-3058 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
pezadeftide - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecule to Disrupt Cell Membrane for Onychomycosis - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
terbinafine hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
terbinafine hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
terbinafine hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
TTY-W - Drug Profile  
Product Description

## Mechanism Of Action

Onychomycosis (Tinea Unguium) - Dormant Projects

Onychomycosis (Tinea Unguium) - Discontinued Products

Onychomycosis (Tinea Unguium) - Product Development Milestones

## Featured News & Press Releases

Jan 12, 2022: Hallux starts phase 2 clinical study of novel subungual gel for onychomycosis

Dec 23, 2021: The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application

Sep 22, 2021: Moberg Pharma receives approval from the EMA's Paediatric Committee

Aug 24, 2021: China patent for pezadeftide granted ACCESS CHINA Biotech Forum presentation investor webinar on 2 September 2021

Jul 26, 2021: Hexima: Completion of enrolment in phase IIb clinical trial

Jul 15, 2021: Hexima: Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar

Jul 14, 2021: Hexima: Grant of European Patent over HXP124

Jun 10, 2021: Moberg Pharma: Phase 3-results for MOB-015 published in JAAD

May 20, 2021: Hexima announces INN designation for HXP124

May 12, 2021: Hexima : Grant of Australian patent over HXP124

Apr 26, 2021: Hexima to present at American Podiatric Medical Association annual conference

Mar 10, 2021: Acceptance of Clenafin/Jublia (efinaconazole) for regulatory review in China

Jan 07, 2021: Updated timeline to phase IIb results

Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021

Sep 14, 2020: Launch of Jublia, a treatment for tinea unguium, in Macau

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Onychomycosis (Tinea Unguim), 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Acea Biotech Inc, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Almirall SA, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Amtixbio Co Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by ASCIL Biopharm, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Blueberry Therapeutics Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by CSA Biotechnologies LLC, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by DermBiont Inc, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Exodos Life Sciences Limited Partnership, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Hallux Inc, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Hexima Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Infextious Therapeutic, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Kaken Pharmaceutical Co Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Moberg Pharma AB, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Mycovia Pharmaceuticals Inc, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by NAL Pharmaceuticals Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Nektr Technologies Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Novabiotics Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Photonamic GmbH & Co KG, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by SaNOtize Research and Development Corp, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by TTY Biopharm Co Ltd, 2022  
Onychomycosis (Tinea Unguim) - Pipeline by Turn Therapeutics Inc, 2022  
Onychomycosis (Tinea Unguim) - Dormant Projects, 2022  
Onychomycosis (Tinea Unguim) - Dormant Projects, 2022 (Contd..1)  
Onychomycosis (Tinea Unguim) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Onychomycosis (Tinea Unguium), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/OEC1A76C4BEBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OEC1A76C4BEBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

